Influence of Comedication on Serum Concentrations of Aripiprazole and Dehydroaripiprazole

被引:65
作者
Waade, Ragnhild Birkeland [1 ,2 ]
Christensen, Hege [2 ]
Rudberg, Ida [1 ]
Refsum, Helge [1 ]
Hermann, Monica [1 ]
机构
[1] Diakonhjemmet Hosp, Dept Psychopharmacol, N-0319 Oslo, Norway
[2] Univ Oslo, Sch Pharm, Dept Pharmaceut Biosci, Oslo, Norway
关键词
aripiprazole; dehydroaripiprazole; drug interaction; pharmacokinetics; therapeutic drug monitoring; PHARMACOKINETIC INTERACTION; PLASMA-CONCENTRATIONS; IN-VITRO; DRUG; RISPERIDONE; ANTIPSYCHOTICS; CARBAMAZEPINE; VOLUNTEERS; CITALOPRAM; OLANZAPINE;
D O I
10.1097/FTD.0b013e3181956726
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Aripiprazole, a relatively new antipsychotic drug, is metabolized by cytochrome P450 3A4 (CYP3A4) and CYP2D6 to an active metabolite, dehydroaripiprazole. As studies on pharmacokinetic drug interactions with aripiprazole are so far limited, the aim of the present study was to investigate the impact of comedication on serum concentrations of aripiprazole and dehydroaripiprazole in psychiatric patients in a clinical setting. A therapeutic drug monitoring database was screened for patients receiving aripiprazole tablets as part of their treatment. Of the 361 samples included, 78% were from patients receiving comedication. The remaining 79 samples constituted the control group. Steady-state dose-adjusted serum concentrations (concentration to dose ratios, C:D ratios) of aripiprazole, dehydroaripiprazole and the sum of aripiprazole and dehydroaripiprazole, and the metabolic ratio (dehydroaripiprazole/aripiprazole) in the different comedication groups were compared with controls. Coadministration of a CYP3A4 inducer resulted in approximately 60% lower mean C:D ratios of aripiprazole, dehydroaripiprazole, and the SLIM of aripiprazole and dehydroaripiprazole (P < 0.05, P < 0.01, and P < 0.01, respectively). Combination with a CYP2D6 inhibitor resulted in a 45% higher mean C:D ratio of aripiprazole (P < 0.05), with no effect on the C:D ratio of dehydroaripiprazole. When aripiprazole was coadministered with alimemazine or lithium, a 56% (P < 0.01) and 43% (P = 0.05) higher mean C:D, ratio of aripiprazole, respectively, was observed. Olanzapine, risperidone injections, escitalopram, or lamotrigine also had statistically significant effects on aripiprazole disposition but to a lesser extent. In conclusion, concurrent treatment with CYP3A4 inducers, CYP2D6 inhibitors, alimemazine, or lithium resulted in changes in the systemic exposure of aripiprazole between 40% and 60%. This is of such a magnitude that dose adjustments of aripiprazole may be required.
引用
收藏
页码:233 / 238
页数:6
相关论文
共 25 条
[1]   The AGNP-TDM expert group consensus guidelines:: Therapeutic Drug Monitoring in psychiatry [J].
Baumann, P ;
Hiemke, C ;
Ulrich, S ;
Eckermann, G ;
Gaertner, I ;
Gerlach, M ;
Kuss, HJ ;
Laux, G ;
Müller-Oerlinghausen, B ;
Rao, ML ;
Riederer, P ;
Zernig, G .
PHARMACOPSYCHIATRY, 2004, 37 (06) :243-265
[2]   Olanzapine - Pharmacokinetic and pharmacodynamic profile [J].
Callaghan, JT ;
Bergstrom, RF ;
Ptak, LR ;
Beasley, CM .
CLINICAL PHARMACOKINETICS, 1999, 37 (03) :177-193
[3]   Effects of comedication on the serum levels of aripiprazole: Evidence from a routine therapeutic drug monitoring service [J].
Castberg, I. ;
Spigset, O. .
PHARMACOPSYCHIATRY, 2007, 40 (03) :107-110
[4]   Pharmacokinetics of aripiprazole and concomitant lithium and valproate [J].
Citrome, L ;
Josiassen, R ;
Bark, N ;
Salazar, DE ;
Mallikaarjun, S .
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (01) :89-93
[5]   Pharmacokinetics of aripiprazole and concomitant carbamazepine [J].
Citrome, Leslie ;
Macher, Jean-Paul ;
Salazar, Daniel E. ;
Mallikaarjun, Suresh ;
Boulton, David W. .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2007, 27 (03) :279-283
[6]  
Davies MA, 2004, CNS DRUG REV, V10, P317
[7]   Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole [J].
Hendset, Magnhild ;
Hermann, Monica ;
Lunde, Hilde ;
Refsum, Helge ;
Molden, Espen .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (12) :1147-1151
[8]   Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: Influence of CYP2D6 polymorphism [J].
Kubo, Masanori ;
Koue, Toshiko ;
Maune, Hiromi ;
Fukuda, Tsuyoshi ;
Azuma, Junichi .
DRUG METABOLISM AND PHARMACOKINETICS, 2007, 22 (05) :358-366
[9]  
Kubo Masanori, 2005, Drug Metab Pharmacokinet, V20, P55, DOI 10.2133/dmpk.20.55
[10]   Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes [J].
Linnet, K .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2002, 17 (05) :233-238